Previous 10 | Next 10 |
BRIDGEWATER, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the second quarter ended June 30, 2021, on August 12, 2021, before the market opens....
VYNE Therapeutics (VYNE) announces the initiation of an investigator initiated trial evaluating the safety and efficacy of AMZEEQ (minocycline) topical foam, 4%, as a companion treatment with oral isotretinoin in patients with moderate to severe acne.The trial is a randomized, multicenter, ev...
BRIDGEWATER, N.J., July 19, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the initiation of an investigator initiated trial (“IIT” or “study”) evaluating the safety and efficac...
VYNE Therapeutics Inc. (NASDAQ:VYNE) traded at a new 52-week low today of $2.63. This new low was reached on below average trading volume as 131,000 shares traded hands, while the average 30-day volume is approximately 934,000 shares. There is potential upside of 101.1% for shares of VYN...
VYNE Therapeutics Inc. (NASDAQ:VYNE) traded today at a new 52-week low of $2.68. This new low was reached on below average trading volume as 131,000 shares traded hands, while the average 30-day volume is approximately 921,000 shares. VYNE Therapeutics Inc is a biopharmaceutical company ...
VYNE stock has depreciated by 65% in the last 3 months. There are no overwhelmingly critical factors behind this. The market, and smart money, just seem to dislike the stock. For further details see: VYNE Therapeutics: Terrible Depreciation Of Shareholder Value
BRIDGEWATER, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that Dr. Iain Stuart, Chief Scientific Officer, will participate in and moderate a scientific panel discussion at the 2 nd Ann...
Alfi (ALF) +35%.SemiLEDs Corporation (LEDS) +19%.Protagenic Therapeutics (PTIX) +18%.Party City Holdco (PRTY) +12% on Q1 results.BioNTech SE (BNTX) +9% on Q1 results.Aptorum Group Limited (APM) +8%.VYNE Therapeutics (VYNE) +8%.Inovio Pharmaceuticals (INO) +8% on positive data f...
iBio (IBIO) +33% on COVID-19 study update.Orgenesis (ORGS) +11% on Q1 results.Chemomab Therapeutics (CMMB) +12%.T2 Biosystems, Inc. (TTOO) +11% on Q1 results.ViewRay (VRAY) +12%.Epizyme (EPZM) +11% on Q1 results.CureVac N.V. (CVAC) +9%.Roku (ROKU) +9% on Q1 results.Da...
Image source: The Motley Fool. VYNE Therapeutics Inc. (NASDAQ: VYNE) Q1 2021 Earnings Call May 06, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: VYNE Therapeutics Inc. (VYNE) Q1 2021 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
VYNE Therapeutics Inc Com Company Name:
VYNE Stock Symbol:
NASDAQ Market:
VYNE Therapeutics Inc Com Website:
BRIDGEWATER, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory con...
BRIDGEWATER, N.J., July 09, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory con...
BRIDGEWATER, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory co...